PAD4 Inhibitor Therapy for Managing Heart Failure and Diabetic Complications

Background

Heart failure and diabetic complications, including cardiomyopathy and nephropathy, are significant global health challenges affecting millions. Heart failure, specifically heart failure with preserved ejection fraction (HFpEF), is characterized by impaired heart relaxation despite normal ejection fraction. This condition affects those with autoimmune diseases, diabetes, hypertension, aging, and obesity. Diabetic cardiomyopathy and nephropathy further complicate diabetes management, contributing to high morbidity and mortality rates due to the interplay of cardiovascular and kidney dysfunctions. Despite advances in therapy, the complications from diabetes—driven by thromboinflammation and neurohormonal changes—perpetuate organ damage, underscoring the need for targeted treatments that provide cardiorenal protection.

Technology Overview

This technology involves the use of protein-arginine deiminase type-4 (PAD4) inhibitors and represents a novel treatment approach for managing heart failure with preserved ejection fraction (HFpEF) and diabetic complications such as cardiomyopathy and nephropathy. PAD4, an enzyme crucial in inflammatory pathways and immune responses, contributes to the pathological processes that lead to fibrosis and organ dysfunction. By inhibiting PAD4 activity, these agents help reduce the thickening and stiffening of the heart muscle observed in HFpEF and counteract the thromboinflammation causing tissue damage in diabetic patients. In preclinical models, PAD4 inhibitors have been shown to reduce PAD4 activity by over 50%, resulting in measurable improvements in cardiac function, including increased ventricular relaxation and enhanced ejection fractions. In rodent models of diabetes, PAD4 inhibition led to significant reductions in biomarkers of inflammation and fibrosis in both the heart and kidneys, demonstrating decreased progression of organ damage and improved overall organ function.

Applications

• Treatment of heart failure with preserved ejection fraction (HFpEF)
• Management of diastolic heart failure and dysfunction
• Mitigation of diabetic cardiomyopathy and nephropathy
• Potential applications in other thromboinflammatory conditions

Advantages

• Specifically targets molecular drivers of heart and kidney dysfunction, offering comprehensive management of complex diabetic complications
• Potential to reverse heart and kidney damage by addressing underlying inflammatory processes
• Enhances treatment outcomes for patients with multifaceted cardiovascular and renal conditions
• Provides a novel therapeutic alternative to current treatments, addressing unmet needs in chronic disease management